Sialidases: Therapeutic and Antiatherogenic Potential

Author(s): Vasily Nikolaevich Sukhorukov*, Vasily Petrovich Karagodin, Emile Rustemovich Zakiev, Andrey Vyacheslavovich Grechko, Alexandr Nikolaevich Orekhov

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 31 , 2017


Become EABM
Become Reviewer
Call for Editor

Abstract:

This review focuses on the biological role and clinical relevance of relatively poor studied enzymes known as sialidases. We describe structure and function of sialic acid, in particular as a component of gangliosides and plasma lipoproteins. Several types of sialidases are known in mammals, of which trans-sialidase is of special interest, since it is capable of removing sialic acid from low density lipoprotein (LDL) particles and transferring it to different acceptors in blood plasma. Desialylation of LDL, in turn, endows it a capacity to accumulate in the smooth muscle cells of human aortic intima, and therefore is important for atherogenesis. Moreover, sialidases appear to be involved in a variety of pathological processes, including viral infections and cancer, which makes these enzymes an attractive therapeutic target.

Keywords: Sialidase, trans-sialidase, desialylation, sialic acid, atherosclerosis, LDL.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 23
ISSUE: 31
Year: 2017
Published on: 04 December, 2017
Page: [4696 - 4701]
Pages: 6
DOI: 10.2174/1381612823666170609082324
Price: $65

Article Metrics

PDF: 33
HTML: 3